76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Amicus Therapeutics Inc
Closed
SectorHealthcare
6.31 4.99
Overview
Share price change
24h
Min
6.3
Max
6.34
Income | -36M -22M |
|---|---|
Sales | -24M 125M |
Profit margin | -17.314 |
Employees | 499 |
EBITDA | -27M -4.8M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +145.25% upside |
Market Cap | -386M 1.9B |
|---|---|
Previous open | 1.32 |
Previous close | 6.31 |
Technical Score
By Trading Central
Confidence
Very Strong Bearish Evidence
Amicus Therapeutics Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Amicus Therapeutics Inc Forecast
Price Target
By TipRanks
145.25% upside
12 Months Forecast
Average 15.5 USD 145.25%
High 20 USD
Low 12 USD
Based on 5 Wall Street analysts offering 12 month price targets forAmicus Therapeutics Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Amicus Therapeutics Inc
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
